Premium
Cisplatin and 5‐fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck
Author(s) -
Kish Julie A.,
Weaver Arthur,
Jacobs John,
Cummings Glenn,
AlSarraf Muhyi
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840501)53:9<1819::aid-cncr2820530903>3.0.co;2-r
Subject(s) - medicine , cisplatin , head and neck cancer , chemotherapy , surgery , fluorouracil , epidermoid carcinoma , bolus (digestion) , progressive disease , radiation therapy , salvage therapy , cancer , urology
The combination of cisplatin and 96‐hour infusion of 5‐fluorouracil (5‐FU) was evaluated in 30 patients with recurrent (local and regional) and disseminated histologically proven epidermoid cancer of the head and neck who failed surgery and radiotherapy. Cisplatin 100 mg/M 2 intravenous (IV) bolus was given on day 1 with hydration and mannitol diuresis; 5‐FU 1000 mg/M 2 per day for 96‐hour infusion was started immediately after cisplatin on day 1. All patients had measurable lesions. Eight (27%) patients achieved complete response (CR), and 13 (43%) had partial response (PR). Overall response rate was 70% (8 of 30 CR and 13 of 30 PR). Response rate in patients with recurrent local and regional disease was 89% (17/19) with median survival of 32 weeks, while response in patients with disseminated disease was 36% (4/11) with median survival of 24 weeks. Patients with good performance status (PS) (<70%) had a response rate of 79% (19/24), while those with poor PS (<70%) had a response rate of 33% (2/6). Seven patients with recurrent disease who had a response to this chemotherapy went to further salvage surgical procedures. It is concluded that the combination of cisplatin and 5‐FU is very effective and well tolerated in these patients, and leads to further salvage in some patients with improved longevity and quality of life.